News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AM-Pharma Holding BV Announces Positive Phase I Data On recAP, For Acute Kidney Injury



3/26/2014 9:47:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BUNNIK, Netherlands--(BUSINESS WIRE)--AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES